期刊
JOURNAL OF CONTROLLED RELEASE
卷 161, 期 2, 页码 225-234出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2011.12.014
关键词
Drug targeting; Nanomedicine; Inflammatory disease; Rheumatoid arthritis; Multiple sclerosis
资金
- MediTrans, an Integrated Project
- European Commission
In various systemic disorders, structural changes in the microenvironment of diseased tissues enable both passive and active targeting of therapeutic agents to these tissues. This has led to a number of targeting approaches that enhance the accumulation of drugs in the target tissues, making drug targeting an attractive strategy for the treatment of various diseases. Remarkably, the strategic principles that form the basis of drug targeting are often employed for tumor targeting, while chronic inflammatory diseases appear to draw much less attention. To provide the reader with a general overview of the current status of drug targeting to inflammatory diseases, the passive and active targeting strategies that have been used for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS) are discussed. The last part of this review addresses the dualism of platform technology-oriented (one for all) and disease-oriented drug targeting research (all for one), both of which are key elements of effective drug targeting research. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据